Willem Elfrink Net Worth

The estimated Net Worth of Willem Elfrink is at least $985 Тысяча dollars as of 11 November 2021. Willem Elfrink owns over 332,407 units of HeartBeam Inc stock worth over $985,187 and over the last 3 years Willem sold BEAT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Willem Elfrink BEAT stock SEC Form 4 insiders trading

Willem has made over 1 trades of the HeartBeam Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Willem exercised 332,407 units of BEAT stock worth $1,396,109 on 11 November 2021.

The largest trade Willem's ever made was exercising 332,407 units of HeartBeam Inc stock on 11 November 2021 worth over $1,396,109. On average, Willem trades about 41,551 units every 0 days since 2021. As of 11 November 2021 Willem still owns at least 437,861 units of HeartBeam Inc stock.

You can see the complete history of Willem Elfrink stock trades at the bottom of the page.

What's Willem Elfrink's mailing address?

Willem's mailing address filed with the SEC is 2118 WALSH AVE, SUITE 210, , SANTA CLARA, CA, 95050.

Insiders trading at HeartBeam Inc

Over the last 11 years, insiders at HeartBeam Inc have traded over $23,124,978 worth of HeartBeam Inc stock and bought 31,500 units worth $221,145 . The most active insiders traders include Joseph H Capper, Heather C Getz и Willem Elfrink. On average, HeartBeam Inc executives and independent directors trade stock every 32 days with the average trade being worth of $55,046. The most recent stock trade was executed by Urioste George De on 6 September 2024, trading 1,674 units of BEAT stock currently worth $3,917.

What does HeartBeam Inc do?

heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.

Complete history of Willem Elfrink stock trades at HeartBeam Inc

HeartBeam Inc executives and stock owners

HeartBeam Inc executives and other stock owners filed with the SEC include:

• Joseph Capper,
  President, Chief Executive Officer, Director
• Heather Getz,
  Chief Financial Officer, Executive Vice President, Chief Administrative Officer
• Fred Broadway,
  President, BioTel Heart
• Daniel Wisniewski,
  Senior Vice President - Technical Operations
• Kirk Gorman,
  Independent Chairman of the Board
• Rebecca Rimel,
  Independent Director
• Anthony Conti,
  Independent Director
• Joseph Frick,
  Independent Director
• Stephan Rietiker,
  Director
• Robert Rubin,
  Independent Director
• Colin Hill,
  Independent Director
• Tiffany Olson,
  Independent Director
• Laura Dietch,
  Independent Director
• Dr. Branislav Vajdic Ph.D.,
  Founder, CEO & Director
• Richard D. Brounstein,
  Chief Financial Officer
• Manish Wadhwa,
  Chief Medical Officer
• Andrei Stoica,
  Chief Technology Officer
• Dr. Peter J. Fitzgerald FACC, M.D., Ph.D.,
  Chief Medical Officer
• Ken Persen,
  Chief Technology Officer
• Dr. Jon Hunt Ph.D.,
  Exec. VP & Chief Bus. Officer
• Alexei Shvilkin M.D.,
  Chief Medical Officer
• Dr. Dorin Panescu Ph.D.,
  Chief Technical Officer
• Alan Baumel,
  Chief Operating Officer
• Richard M. Ferrari,
  Exec. Chairman
• George Hrenko,
  Senior Vice President
• Stephen Rietiker,
  Director
• Michael Geldart,
  Senior Vice President
• Ronald A Ahrens,
  Director
• Eric N Prystowsky,
  Director
• Peter Ferola,
  SVP & General Counsel
• Kenneth Warwick Iii Nelson,
  Director
• Mark E Strome,
  10% owner
• Michael R Jaff,
  Director
• Willem Elfrink,
  Director
• Marga Ortigas Wedekind,
  Director
• Urioste George De,
  Director
• Richard Ferrari,
  Director
• Jon Patrick Hunt,
  Chief Business Officer
• Richard Brounstein,
  Chief Financial Officer
• Alan Baumel,
  Chief Operating Officer
• Kenneth Harry Persen,
  Chief Technology Officer
• Robert Paul Eno,
  President
• Branislav Vajdic,
  CHIEF EXECUTIVE OFFICER